Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels

S. Tsuda, S. Misawa, S. Horiike, K. Hirakawa, Y. Kuzuyama, Hiroyuki Nakai, T. Seryu, T. Takashima, M. Taniwaki, K. Kashima, S. Tanaka, S. Yokota, H. Nishigaki, K. Nishida, H. Nakagawa, H. Fujii, H. Imanishi, T. Nakai, Y. Ohkawara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma. Plasma β-D-glucan levels, the differences between the levels determined toxicolor test and in endospecy test, were also investigated. Fourteen patients with systemic mycoses and 31 patients with suspected mycotic infections were treated with intravenous administration of FLCZ at a daily dose of 400 mg. Exellent to good responses were observed in 4 of the 14 patients (28.6%) with definitive diagnosis of mycosis, and in 18 of the 31 patients (58.1%) with suspected fungal infections, with an overall efficacy rate of 48.9% (22/45). Levels of plasma β-D-glucan correlated well with efficacies of FLCZ in 19 of 30 patients. In several cases, however, plasma β-D-glucan levels were low during the entire course of treatment. Even in 10 cases of definite mycosis, 4 cases showed low levels of plasma β-D-glucan (below 15 pg/ml by repeated determinations). The results indicate that FLCZ is an effective agent for the treatment of severe systemic fungal infections in patients with hematologic disorders. Deep seated mycosis cannot be ruled out even when its plasma levels of β-D- glucan are low.

Original languageEnglish (US)
Pages (from-to)901-911
Number of pages11
JournalJapanese Journal of Antibiotics
Volume46
Issue number10
StatePublished - 1993
Externally publishedYes

Fingerprint

Mycoses
Fluconazole
Hematologic Neoplasms
Triazoles
polyglucosan
Myelodysplastic Syndromes
Intravenous Administration
Lymphoma
Leukemia
Therapeutics
Infection

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels. / Tsuda, S.; Misawa, S.; Horiike, S.; Hirakawa, K.; Kuzuyama, Y.; Nakai, Hiroyuki; Seryu, T.; Takashima, T.; Taniwaki, M.; Kashima, K.; Tanaka, S.; Yokota, S.; Nishigaki, H.; Nishida, K.; Nakagawa, H.; Fujii, H.; Imanishi, H.; Nakai, T.; Ohkawara, Y.

In: Japanese Journal of Antibiotics, Vol. 46, No. 10, 1993, p. 901-911.

Research output: Contribution to journalArticle

Tsuda, S, Misawa, S, Horiike, S, Hirakawa, K, Kuzuyama, Y, Nakai, H, Seryu, T, Takashima, T, Taniwaki, M, Kashima, K, Tanaka, S, Yokota, S, Nishigaki, H, Nishida, K, Nakagawa, H, Fujii, H, Imanishi, H, Nakai, T & Ohkawara, Y 1993, 'Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels', Japanese Journal of Antibiotics, vol. 46, no. 10, pp. 901-911.
Tsuda, S. ; Misawa, S. ; Horiike, S. ; Hirakawa, K. ; Kuzuyama, Y. ; Nakai, Hiroyuki ; Seryu, T. ; Takashima, T. ; Taniwaki, M. ; Kashima, K. ; Tanaka, S. ; Yokota, S. ; Nishigaki, H. ; Nishida, K. ; Nakagawa, H. ; Fujii, H. ; Imanishi, H. ; Nakai, T. ; Ohkawara, Y. / Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels. In: Japanese Journal of Antibiotics. 1993 ; Vol. 46, No. 10. pp. 901-911.
@article{ee859e77fca94ee4b908d66b6001e49c,
title = "Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels",
abstract = "Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma. Plasma β-D-glucan levels, the differences between the levels determined toxicolor test and in endospecy test, were also investigated. Fourteen patients with systemic mycoses and 31 patients with suspected mycotic infections were treated with intravenous administration of FLCZ at a daily dose of 400 mg. Exellent to good responses were observed in 4 of the 14 patients (28.6{\%}) with definitive diagnosis of mycosis, and in 18 of the 31 patients (58.1{\%}) with suspected fungal infections, with an overall efficacy rate of 48.9{\%} (22/45). Levels of plasma β-D-glucan correlated well with efficacies of FLCZ in 19 of 30 patients. In several cases, however, plasma β-D-glucan levels were low during the entire course of treatment. Even in 10 cases of definite mycosis, 4 cases showed low levels of plasma β-D-glucan (below 15 pg/ml by repeated determinations). The results indicate that FLCZ is an effective agent for the treatment of severe systemic fungal infections in patients with hematologic disorders. Deep seated mycosis cannot be ruled out even when its plasma levels of β-D- glucan are low.",
author = "S. Tsuda and S. Misawa and S. Horiike and K. Hirakawa and Y. Kuzuyama and Hiroyuki Nakai and T. Seryu and T. Takashima and M. Taniwaki and K. Kashima and S. Tanaka and S. Yokota and H. Nishigaki and K. Nishida and H. Nakagawa and H. Fujii and H. Imanishi and T. Nakai and Y. Ohkawara",
year = "1993",
language = "English (US)",
volume = "46",
pages = "901--911",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "10",

}

TY - JOUR

T1 - Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma β-D-glucan levels

AU - Tsuda, S.

AU - Misawa, S.

AU - Horiike, S.

AU - Hirakawa, K.

AU - Kuzuyama, Y.

AU - Nakai, Hiroyuki

AU - Seryu, T.

AU - Takashima, T.

AU - Taniwaki, M.

AU - Kashima, K.

AU - Tanaka, S.

AU - Yokota, S.

AU - Nishigaki, H.

AU - Nishida, K.

AU - Nakagawa, H.

AU - Fujii, H.

AU - Imanishi, H.

AU - Nakai, T.

AU - Ohkawara, Y.

PY - 1993

Y1 - 1993

N2 - Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma. Plasma β-D-glucan levels, the differences between the levels determined toxicolor test and in endospecy test, were also investigated. Fourteen patients with systemic mycoses and 31 patients with suspected mycotic infections were treated with intravenous administration of FLCZ at a daily dose of 400 mg. Exellent to good responses were observed in 4 of the 14 patients (28.6%) with definitive diagnosis of mycosis, and in 18 of the 31 patients (58.1%) with suspected fungal infections, with an overall efficacy rate of 48.9% (22/45). Levels of plasma β-D-glucan correlated well with efficacies of FLCZ in 19 of 30 patients. In several cases, however, plasma β-D-glucan levels were low during the entire course of treatment. Even in 10 cases of definite mycosis, 4 cases showed low levels of plasma β-D-glucan (below 15 pg/ml by repeated determinations). The results indicate that FLCZ is an effective agent for the treatment of severe systemic fungal infections in patients with hematologic disorders. Deep seated mycosis cannot be ruled out even when its plasma levels of β-D- glucan are low.

AB - Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma. Plasma β-D-glucan levels, the differences between the levels determined toxicolor test and in endospecy test, were also investigated. Fourteen patients with systemic mycoses and 31 patients with suspected mycotic infections were treated with intravenous administration of FLCZ at a daily dose of 400 mg. Exellent to good responses were observed in 4 of the 14 patients (28.6%) with definitive diagnosis of mycosis, and in 18 of the 31 patients (58.1%) with suspected fungal infections, with an overall efficacy rate of 48.9% (22/45). Levels of plasma β-D-glucan correlated well with efficacies of FLCZ in 19 of 30 patients. In several cases, however, plasma β-D-glucan levels were low during the entire course of treatment. Even in 10 cases of definite mycosis, 4 cases showed low levels of plasma β-D-glucan (below 15 pg/ml by repeated determinations). The results indicate that FLCZ is an effective agent for the treatment of severe systemic fungal infections in patients with hematologic disorders. Deep seated mycosis cannot be ruled out even when its plasma levels of β-D- glucan are low.

UR - http://www.scopus.com/inward/record.url?scp=0027446682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027446682&partnerID=8YFLogxK

M3 - Article

C2 - 8254892

AN - SCOPUS:0027446682

VL - 46

SP - 901

EP - 911

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 10

ER -